XML 38 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Restatement of Previously Issued Consolidated Financial Statements (Tables)
3 Months Ended
Mar. 31, 2024
Prior Period Adjustment [Abstract]  
Summary of Impact of Correction of Misstatements

The impact of the correction of the misstatements is summarized below (in thousands):

 

 

As of March 31, 2024

 

Corrected Condensed Consolidated Balance Sheets (Unaudited)

 

As Previously Reported

 

 

Restatement Impact

 

 

As Restated

 

Warrant liabilities

 

 

 

 

 

89,547

 

 

 

89,547

 

Total liabilities

 

 

5,999

 

 

 

89,547

 

 

 

95,546

 

Common stock

 

 

25

 

 

 

 

 

 

25

 

Additional paid-in capital

 

 

328,280

 

 

 

 

 

 

328,280

 

Accumulated deficit

 

 

(253,486

)

 

 

(89,547

)

 

 

(343,033

)

Total Stockholders' Equity (Deficit)

 

$

74,819

 

 

$

(89,547

)

 

$

(14,728

)

 

 

 

 

Three Months Ended March 31, 2024

 

Corrected Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

 

As Previously Reported

 

 

Restatement Impact

 

 

As Restated

 

Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds

 

 

 

 

 

(13,336

)

 

 

(13,336

)

Net loss and comprehensive loss

 

$

(10,295

)

 

$

(13,336

)

 

$

(23,631

)

Net loss per share, basic and diluted

 

$

(0.34

)

 

$

(0.45

)

 

$

(0.79

)

 

 

 

 

Three Months Ended March 31, 2024

 

 

 

Accumulated Deficit

 

 

Total Stockholders' Equity (Deficit)

 

Corrected Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)

 

As
Previously
Reported

 

 

Restatement
Impact

 

 

As
Restated

 

 

As
Previously
Reported

 

 

Restatement
Impact

 

 

As
Restated

 

Balance as of December 31, 2023

 

$

(243,191

)

 

$

(76,211

)

 

$

(319,402

)

 

$

83,419

 

 

$

(76,211

)

 

$

7,208

 

Issuance of common stock in connection with exercise of pre-funded warrants

 

 

 

 

 

 

 

 

 

 

 

1

 

 

 

 

 

 

1

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

1,694

 

 

 

 

 

 

1,694

 

Net loss and comprehensive loss

 

 

(10,295

)

 

 

(13,336

)

 

 

(23,631

)

 

 

(10,295

)

 

 

(13,336

)

 

 

(23,631

)

Balance as of March 31, 2024 (As Restated)

 

$

(253,486

)

 

$

(89,547

)

 

$

(343,033

)

 

$

74,819

 

 

$

(89,547

)

 

$

(14,728

)

 

 

 

 

Three Months Ended March 31, 2024

 

Corrected Condensed Consolidated Statements of Cash Flows (Unaudited)

 

As Previously Reported

 

 

Restatement Impact

 

 

As Restated

 

Net loss

 

$

(10,295

)

 

$

(13,336

)

 

$

(23,631

)

Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds

 

 

 

 

 

13,336

 

 

 

13,336

 

Net cash used in operating activities

 

$

(8,741

)

 

$

-

 

 

$

(8,741

)